Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants
- PMID: 16829763
- DOI: 10.1097/00006231-200608000-00005
Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants
Abstract
Objective: To investigate whether recombinant human thyroid-stimulating factor (rhTSH) is effective for the radiometabolic ablation of post-surgery thyroid remnants, using low doses of (131)I.
Patients and methods: The study included two groups of patients enrolled consecutively: group 1 consisted of 52 patients with papillary cancer or minimally invasive follicular cancer (stage I and II), and group 2 consisted of 41 patients with the same stage of disease. All patients underwent a total thyroidectomy. Group 1 received 1.11 GBq (30 mCi) (131)I for post-surgical remnants ablation with the aid of rhTSH, while group 2, in the hypothyroid state, received the same amount of radioiodine. To minimize iodine interference, all patients remained on a low iodine diet for 2 weeks and L-thyroxine (L-T4) was stopped for 4 days in the group of patients treated with the aid of rhTSH. To investigate (131)I uptake in this group, a tracer dose was administered 3 h after the second injection of rhTSH and the uptake was evaluated at 24 h just before administration of the therapeutic dose. I was also measured in the patients treated in the hypothyroid state just before the therapeutic dose was given.
Results: After 1 year both groups were studied by using whole-body scintigraphy (WBS) and measuring thyroglobulin after rhTSH. In group 1, WBS was negative in 76.9% (40 patients), while thyroglobulin-stimulated levels were <1.0 ng . ml(-1) in 86.5% (45 patients). In Group 2, WBS was negative in 75.6% (31 patients), while thyroglobulin-stimulated levels were <1 ng . ml(-1) in 78.0% (32 patients). (131)I uptake was 2.29+/-0.45 in the group treated with the aid of rhTSH, and 3.30+/-0.7 in the group treated in the hypothyroid state (P=0.2). No patients treated with the aid of rhTSH and with the short stoppage of L-T4 experienced symptoms of hypothyroidism, and free thyroxine (FT4) and thyroid-stimulating hormone levels remained normal.
Conclusions: Our data confirm that, when the interference of iodine is minimized, rhTSH is highly effective for the treatment of post-surgical thyroid remnants using a low dose of (131)I.
Similar articles
-
Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.J Clin Endocrinol Metab. 2003 Sep;88(9):4110-5. doi: 10.1210/jc.2003-030298. J Clin Endocrinol Metab. 2003. PMID: 12970272 Clinical Trial.
-
Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium.Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):242-9. doi: 10.1007/s00259-009-1254-2. Epub 2009 Sep 4. Eur J Nucl Med Mol Imaging. 2010. PMID: 19760415 Clinical Trial.
-
Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients.Eur J Endocrinol. 2009 Mar;160(3):431-6. doi: 10.1530/EJE-08-0669. Epub 2008 Dec 12. Eur J Endocrinol. 2009. PMID: 19074463 Clinical Trial.
-
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.Endocr Relat Cancer. 2005 Mar;12(1):49-64. doi: 10.1677/erc.1.00830. Endocr Relat Cancer. 2005. PMID: 15788638 Review.
-
Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when.Eur J Surg Oncol. 2007 Jun;33(5):535-40. doi: 10.1016/j.ejso.2007.01.017. Epub 2007 Mar 6. Eur J Surg Oncol. 2007. PMID: 17337154 Review.
Cited by
-
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2267-76. doi: 10.1007/s00259-010-1565-3. Epub 2010 Jul 27. Eur J Nucl Med Mol Imaging. 2010. PMID: 20661558
-
Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management.Onco Targets Ther. 2009 Jan 1;1:87-101. doi: 10.2147/ott.s3480. Onco Targets Ther. 2009. PMID: 21127756 Free PMC article.
-
The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials.J Korean Med Sci. 2014 Jun;29(6):811-7. doi: 10.3346/jkms.2014.29.6.811. Epub 2014 May 30. J Korean Med Sci. 2014. PMID: 24932083 Free PMC article.
-
TSH-β gene polymorphism in Saudi patients with thyroid cancer: A case-control study.Saudi Pharm J. 2022 Nov;30(11):1538-1542. doi: 10.1016/j.jsps.2022.07.015. Epub 2022 Jul 29. Saudi Pharm J. 2022. PMID: 36465847 Free PMC article.
-
The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients.Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):673-80. doi: 10.1007/s00259-010-1689-5. Epub 2011 Jan 6. Eur J Nucl Med Mol Imaging. 2011. PMID: 21210115
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical